November 2025
1. LANDMESSER U, Laufs U, Schatz U, Winzer EB, et al
   Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran's early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hyp
   Am Heart J. 2025;289:117-126.
   

   >> Share

   
   August 2025
2. MARSTON NA, Bergmark BA, Alexander VJ, Karwatowska-Prokopczuk E, et al
   Design and rationale of the CORE-TIMI?72a and CORE2-TIMI?72b trials of olezarsen in patients with severe hypertriglyceridemia.
   Am Heart J. 2025;286:125-135.
   

   >> Share

   
   July 2025
3. MAKUVIRE TT, Latif Z, Atwater S, Shah MK, et al
   Health Care Access and Risk Factor Control in US adults with Cardiovascular Disease from 2015 to 2023.
   Am Heart J. 2025 Jul 2:S0002-8703(25)00208-X. doi: 10.1016/j.ahj.2025.
   

   >> Share

   
   March 2025
4. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
   Olezarsen in Patients with Hypertriglyceridemia at High Cardiovascular Risk: Rationale and Design of the Essence-TIMI 73b Trial.
   Am Heart J. 2025 Mar 11:S0002-8703(25)00072-9. doi: 10.1016/j.ahj.2025.
   

   >> Share

   
   February 2025
5. TIAN Y, Wang X, Hu Z, Yu X, et al
   Design, rationale, and characterization of the Mobile health based OccuPational cardiovascular risk intErventioN study (mHealth-OPEN Study).
   Am Heart J. 2025 Feb 13:S0002-8703(25)00035-3. doi: 10.1016/j.ahj.2025.
   

   >> Share

   
   December 2024
6. IKEMURA N, Chan PS, Gosch K, Nguyen DD, et al
   Health Status Outcomes after Acute Myocardial Infarction in Patients without Standard Modifiable Risk Factors.
   Am Heart J. 2024 Dec 3:S0002-8703(24)00317-X. doi: 10.1016/j.ahj.2024.
   

   >> Share

   
   October 2024
7. VASSY JL, Brunette CA, Yi T, Harrison A, et al
   Design and pilot results from the Million Veteran Program Return Of Actionable Results (MVP-ROAR) Study.
   Am Heart J. 2024;276:99-109.
   

   >> Share

   
   May 2024
8. NICHOLLS SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al
   Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN.
   Am Heart J. 2024 May 3:S0002-8703(24)00116-9. doi: 10.1016/j.ahj.2024.
   

   >> Share

   
   October 2023
9. ALNEWAIS ME, Adams L, Alfehaid AS, Alzaidi S, et al
   Geographic distribution of United States clinical trial sites utilized for guideline changing studies of cholesterol management.
   Am Heart J. 2023;264:174-176.
   

   >> Share

   
   January 2023
10. SAITO Y, Inohara T, Kohsaka S, Wada H, et al
    Characteristics and outcomes of patients with no standard modifiable risk factors undergoing primary revascularization for acute myocardial infarction: Insights from the nationwide J-PCI registry.
    Am Heart J. 2023 Jan 12:S0002-8703(23)00017-0. doi: 10.1016/j.ahj.2023.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share